The PD-1 and PD-L1 inhibitors market comprises immunotherapy drugs that help boost the body’s natural defenses to fight against cancer. These drugs work by blocking proteins called PD-1 and PD-L1 that help tumors from hiding from the immune system. Some of the major products in this market include nivolumab, pembrolizumab, atezolizumab and durvalumab. These drugs are used for treatment of various types of cancer such as melanoma, lung cancer, bladder cancer and Hodgkin’s lymphoma.
The global PD-1 And PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 billion in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Rising prevalence of cancer globally is a major driver of the PD-1 and PD-L1 inhibitor market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and about 10 million deaths occur every year due to cancer. Many factors such as increasing geriatric population, growing adoption of sedentary and unhealthy lifestyles along with changing environmental conditions are contributing to the rising burden of cancer worldwide. This growing cancer incidence in turn is increasing the demand for effective treatment options like PD-1 and PD-L1 inhibitors. Furthermore, rising approval of these drugs for additional cancer types is also boosting market growth. For instance, nivolumab and pembrolizumab have now received approval for treatment of head and neck squamous cell carcinoma, urothelial carcinoma and Merkel cell carcinoma. Thus, growing cancer burden along with increasing approval of these drugs is driving up uptake of PD-1 and PD-L1 inhibitors globally.
The PD-1 and PD-L1 inhibitor market is dominated by the immuno-oncology sub segment which accounts for around 60% of the overall market share. This is because immuno-oncology drugs have shown promising results in the treatment of various cancer types like lung cancer, melanoma, head & neck cancer, kidney cancer and others. These drugs help boost the body’s natural defenses to fight cancer by blocking protein interaction between PD-1 and its ligands PD-L1/PD-L2.
Political: The market is positively impacted by the government initiatives and support for research & development of novel immunotherapies through funding. However, stringent regulations for approval of new drugs acts as a restraint.
Economic: Rising healthcare expenditure, increasing affluence, growing demand for advanced cancer therapies propel the market growth. However, high costs of drug development and treatment pose challenges.
Social: Increasing incidence of cancer worldwide due to changing lifestyle habits, growing awareness about innovative treatment options influence the market.
Technological: Significant research into PD-1 and PD-L1 pathway leading to launch of newer drugs with improved efficacy and less side effects expands scope. Combination therapies show promise.
The global PD-1 And PD-L1 Inhibitor Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The global PD-1 and PD-L1 inhibitor market is estimated to be valued at US$ 39.83 billion in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030.
North America currently dominates the market due to early approval and access to innovative therapies, rising cancer burden, and presence of major players. The Asia Pacific region also offers tremendous scope for growth due to rising healthcare infrastructure, large cancer patient pool, and increasing healthcare expenditures.
Key players operating in the PD-1 and PD-L1 inhibitor market are Sesajal S.A. de C.V., Olivado, Grupo Industrial Batellero S.A. de C.V, YASIN, Tron Hermanos SA de CV, The Village Press, Bella Vado, Chosen Foods LLC, and Storino’s Quality Products. These companies have a strong foothold due to their diverse product portfolios and global presence.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it